Rhythm Pharmaceuticals (RYTM) CHRO awarded RSUs and 17,500 stock options

Rhea-AI Filing Summary

Rhythm Pharmaceuticals’ Chief Human Resources Officer Pamela J. Cramer received new equity awards. On February 11, 2026, she was granted 11,650 restricted stock units, each representing one share of common stock. These RSUs vest in four equal 25% installments on February 1 of 2027, 2028, 2029, and 2030.

She was also granted stock options for 17,500 shares of common stock at an exercise price of $98.47 per share. These options vest in 16 substantially equal installments, based on completing each three full months of successive service after the grant date. All awards are held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cramer Pamela J.

Role Chief Human Resources Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	11,650	$0.00	--
Grant/Award	Stock Options (Right to Buy)	17,500	$0.00	--

Holdings After Transaction: Restricted Stock Units — 11,650 shares (Direct); Stock Options (Right to Buy) — 17,500 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cramer Pamela J.

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/11/2026		A		11,650		(2)	(2)	Common Stock	11,650	$0	11,650	D
Stock Options (Right to Buy)	$98.47	02/11/2026		A		17,500		(3)	02/10/2036	Common Stock	17,500	$0	17,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

3. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did RYTM Chief Human Resources Officer Pamela J. Cramer receive?

Pamela J. Cramer received two equity awards: 11,650 restricted stock units and stock options covering 17,500 shares of Rhythm Pharmaceuticals common stock. Both grants were made on February 11, 2026, as part of her compensation and are reported as directly owned.

How do Pamela J. Cramer’s restricted stock units at RYTM vest over time?

Cramer’s 11,650 restricted stock units vest in four equal installments of 25%. Vesting occurs on February 1, 2027, 2028, 2029, and 2030. Once vested, each restricted stock unit represents the right to receive one share of Rhythm Pharmaceuticals common stock.

What are the key terms of Pamela J. Cramer’s stock options at Rhythm Pharmaceuticals (RYTM)?

Cramer’s stock options cover 17,500 shares of Rhythm Pharmaceuticals common stock at an exercise price of $98.47 per share. Granted February 11, 2026, they vest in 16 substantially equal installments, tied to completing each three full months of successive service.

Are Pamela J. Cramer’s new Rhythm Pharmaceuticals equity awards direct or indirect holdings?

The filing reports Pamela J. Cramer’s 11,650 restricted stock units and 17,500 stock options as directly owned. There is no indication of indirect ownership through entities or family members, and no footnote disclaiming beneficial ownership or voting and investment authority.

Do Pamela J. Cramer’s restricted stock units at RYTM have an expiration date?

The restricted stock units granted to Cramer have no expiration date. They vest 25% each on February 1 of 2027, 2028, 2029, and 2030. After vesting, each unit entitles her to receive one share of Rhythm Pharmaceuticals common stock.

When did Rhythm Pharmaceuticals grant equity awards to Pamela J. Cramer?

Rhythm Pharmaceuticals granted Pamela J. Cramer 11,650 restricted stock units and 17,500 stock options on February 11, 2026. The Form 4 identifies this as the earliest transaction date and classifies both grants as acquisitions under transaction code “A.”